NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Clinical trial NCT06012695 · RECRUITING
Trial details
- NCT number
- NCT06012695
- Sponsor
- Novelwise Pharmaceutical Corporation
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-11
- Primary completion
- 2028-05-30
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.